Sorafenib Compared to Placebo when Administered in Combination with...
Objective Overview Eligibility Requirements Contact Centers California Cancer CareJaime Changjchang@cal-cancer-care.com415-925-5040
View ArticleA randomized, phase II study of VEGF, RAF kinase and mTOR combination...
Objective Overview Eligibility Requirements Contact Centers California Cancer CareJaime Changjchang@cal-cancer-care.com415-925-5040
View ArticleA Phase I Dose Escalation Study of OMP-21M18 in Subjects with Solid Tumors
Objective Overview Eligibility Requirements Contact Centers California Cancer CareJaime Changjchang@cal-cancer-care.com415-925-5040
View ArticleA Phase III, open label study of Rituximab faster infusion time in patients...
Objective Overview Eligibility Requirements Contact Centers California Cancer CareJaime Changjchang@cal-cancer-care.com415-925-5040
View ArticleBone Marrow and Peripheral Blood Collection from Disease-Specific Donors for...
Objective Overview Eligibility Requirements Contact Centers California Cancer CareJaime Changjchang@cal-cancer-care.com415-925-5040
View ArticleA Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine...
Objective Overview Eligibility Requirements
View ArticleA Phase III Randomized Open-Label 3 Arm Study to Determine the Efficacy and...
Objective Overview Eligibility Requirements
View ArticleVitamin D Supplementation for Musculoskeletal Toxicity in Breast Cancer...
Objective Overview Eligibility Requirements Contact Centers Maine Center For Cancer Medicine & Blood Disorders100 Campus Drive, Suite 108ScarboroughMaine04074Frederick Aronson,...
View ArticleRandomized Phase III Trial of Gemcitabine/Carboplatin with or without BSI-201...
Objective Overview Eligibility Requirements Contact Centers Maine Center For Cancer Medicine & Blood Disorders100 Campus Drive, Suite 108ScarboroughMaine04074Frederick Aronson,...
View ArticleA randomized, open-label, Phase II, 2-arm multi-center trial comparing...
Objective To estimate the hazard ratio for the progression free survival in subjects with advanced NSCLC given maintenance therapy of pazopanib (Arm A) relative to pemetrexed (Arm B). Also to evaluate...
View Article
